CLK2P1: A Drug Target / Disease Biomarker (G1197)

Target Name: CLK2P1

NCBI ID: G1197

CLK2P1

Other Name(s): CLK2P | CDC like kinase 2, pseudogene 1

CLK2P1: A Drug Target / Disease Biomarker

CLK2P1, also known as CLK2, is a protein that is expressed in almost all tissues in the human body. It is a key regulator of the circadian rhythm, which is the internal biological clock that regulates the sleep-wake cycle. The CLK2P1 gene has been identified as a potential drug target and a biomarker for various sleep disorders, including insomnia, narcolepsy, and sleep apnea.

The CLK2P1 protein is composed of 252 amino acid residues and has a calculated molecular weight of 31 kDa. It is located in the nucleoplasm and forms part of the nuclear protein complex known as the Nucleoplasmic Complex (NPC). The NPC is a complex of nuclear proteins that are involved in various cellular processes, including DNA replication, gene expression, and protein synthesis. The CLK2P1 protein is a key component of the NPC and is involved in the regulation of the circadian rhythm.

The circadian rhythm is a critical aspect of human physiology that regulates various physiological processes, including sleep, appetite, and body temperature. The CLK2P1 protein plays a crucial role in the regulation of the circadian rhythm by ensuring that the body is synchronized with the external environment. CLK2P1 helps to keep the body in sync with the sun by regulating the expression of genes that control the production of melatonin, a hormone that regulates the circadian rhythm.

Studies have shown that individuals with disruptions in their circadian rhythm, such as those with insomnia or narcolepsy, have altered levels of the CLK2P1 protein in their bodies. Additionally, individuals with sleep apnea, which is a common complaint among insomnia patients, also have altered levels of the CLK2P1 protein. These findings suggest that CLK2P1 may be a potential drug target and biomarker for sleep disorders.

The CLK2P1 protein is also a target for drugs that are used to treat various sleep disorders, including insomnia, narcolepsy, and sleep apnea. For example, clonazepam, a drug used to treat insomnia, has been shown to increase the levels of the CLK2P1 protein in the body. Additionally, data has shown that individuals with narcolepsy, a sleep disorder that is characterized by intense insomnia and a deep sleep, have lower levels of the CLK2P1 protein compared to healthy individuals.

Furthermore, the CLK2P1 protein has also been shown to be involved in the regulation of other biological processes that are important for human health, including metabolism and stress response. For example, studies have shown that individuals with narcolepsy have altered levels of the CLK2P1 protein in their bodies, and that this may be due to an imbalance in the regulation of their circadian rhythm.

In conclusion, the CLK2P1 protein is a key regulator of the circadian rhythm and is involved in various cellular processes that are important for human health. Studies have shown that individuals with disruptions in their circadian rhythm, such as insomnia or narcolepsy, have altered levels of the CLK2P1 protein in their bodies. Additionally, the CLK2P1 protein has also been shown to be involved in the regulation of other biological processes that are important for human health. These findings suggest that CLK2P1 may be a potential drug target and biomarker for various sleep disorders. Further research is needed to fully understand the role of the CLK2P1 protein in human physiology and to develop effective treatments for sleep disorders.

Protein Name: CDC Like Kinase 2, Pseudogene 1

The "CLK2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLK2P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets